Categories: News

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV

Allée de la Recherche 60, 1070 Brussels

Contact: investorrelations@financiere-tubize.be

Annual Report 2023

Regulated information
16 March 2024

The board of directors of Financière de Tubize has established the 2023 annual report. This report is available on the website www.financiere-tubize.be

  • Profit for the financial year: € 88.2 million (€ 85.2 million in 2022, +3,5%),
  • Increase of outstanding bank borrowings from € 47.8 million at 31 December 2022 to € 79.2 million at 31 December 2023,
  • Acquisition of 1,043,881 UCB shares, increasing the holding of the Company in UCB from 35.70% on 31 December 2022 to 36.24% on 31 December 2023.

If the general shareholders meeting of 26 April 2024 approves the 2023 annual accounts, including the proposed result appropriation, a gross dividend of € 0.97 (compared to €0.86 for financial year 2022, an increase of 12.8%) will be payable as from 3rd of May 2024 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 19.

Ex-dividend          30 April 2024
Record date          2 May 2024
Payment date       3 May 2024

Staff

Recent Posts

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

12 hours ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

12 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

12 hours ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

12 hours ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…

12 hours ago

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction…

12 hours ago